Quick answer: The prior authorization automation platforms a nephrology practice should shortlist in 2026 are Honey Health, Waystar, CoverMyMeds, Availity, Silna Health, and Cohere Health. They differ mainly on three axes: whether prior authorization is a standalone product or bundled into a larger revenue cycle suite, whether they handle medical authorizations or lean pharmacy-only, and how deeply they integrate with your EHR. For nephrology specifically, the differentiator is whether the platform treats recurring dialysis authorizations as tracked objects that expire, or as one-off requests.
How we chose the platforms on this list
A vendor list is only useful if you can see the filter. Here's ours.
To make this list, a platform had to meet all five:
- Actively serving US healthcare providers in 2026, not payers only
- AI-driven automation of at least determination and packet assembly, not just a portal aggregator
- Native EHR integration, with the ability to read structured clinical data rather than requiring manual entry
- Published HIPAA posture — BAA available, security documentation on request
- Documented Medicare Advantage payer coverage, since MA is where nephrology's authorization burden concentrates
Honey Health appears first because this is Honey Health's site, and pretending otherwise would insult you. The remaining five are presented in no particular order, with the same treatment for each: what it does, who it fits, and where it falls short. None of them is graded, because a platform that's wrong for a six-nephrologist independent group can be exactly right for a 40-site MSO.
The nephrology test any platform has to pass
Before the list, the question that separates a nephrology-capable platform from a general one.
Nephrology's authorization volume isn't shaped like most specialties'. Your patients are on therapy indefinitely — dialysis, ESAs, post-transplant immunosuppression — so a large share of your PA work is re-authorization on a schedule rather than fresh requests. Payers, meanwhile, treat ongoing kidney failure as though it needed periodic revalidation.
That creates a failure mode most PA tools aren't built for: the authorization that quietly expires. Claims deny weeks later, get coded generically as "no auth on file," and get worked one at a time by billing staff who never see the pattern.
So the test is a single question to ask every vendor: does your platform track authorization expiration dates and initiate renewal before they lapse, or does it wait for a new order? Everything else on the evaluation checklist matters less than this one.
Two secondary tests worth running:
- Can it read discrete lab values with draw dates — hemoglobin, ferritin, transferrin saturation — so ESA and IV iron packets meet payer recency windows on first submission?
- Does it distinguish SGLT2 inhibitor indications, since step therapy through metformin generally applies to the type 2 diabetes indication but not to the CKD or heart failure indications?
Vendors who handle those three cleanly have done specialty configuration. Vendors who answer in generalities are showing you a generic engine.
The platforms
Honey Health
Honey Health is an AI-native platform built around a set of back-office agents — prior authorization, denial management, referral intake, fax triage, eligibility, refills, data fetching, and payment posting — that run as continuous queues rather than as request-by-request tools.
For nephrology, the relevant design choice is that the prior authorization agent treats each authorization as a tracked object with an expiration date, initiating renewal on a lead time rather than reacting to a new order. The denial management agent works whatever still gets rejected and feeds the denial reason back into how the next packet gets built, so the two operate as a loop rather than as separate products.
Fits: mid-to-large independent practices, multi-specialty groups, and PE-backed MSOs that want authorization and denials handled by the same system, and that have enough recurring-authorization volume for expiration tracking to matter.
Honest weakness: Honey Health is a newer company than the incumbents on this list. If your procurement process weights vendor age and installed base heavily, or if you need prior authorization bundled with claims scrubbing and patient billing from a single contract, one of the established suites will fit your process better.
Waystar
Waystar is a large, publicly traded revenue cycle platform whose Authorization Manager uses rules and automation to determine whether authorization is required, initiate requests, and track status inside a single workflow.
The argument for Waystar is consolidation. If you're already running Waystar for claims and denials, adding authorizations means one vendor relationship, one contract, and one support path — which for a group with a small IT function is a real operational advantage rather than a procurement convenience.
Fits: health systems and larger groups that want prior authorization bundled with claims and denials, and that already have a Waystar footprint.
Honest weakness: breadth comes at the cost of specialty depth. A platform serving every specialty configures for the common cases, and nephrology's recurring-authorization and lab-gated criteria sit outside those. Ask specifically about dialysis re-authorization tracking rather than assuming a large suite covers it.
CoverMyMeds
CoverMyMeds, part of McKesson, is the highest-volume electronic prior authorization network in the market, integrated with hundreds of EHRs and connected to most major payers. It works inside existing prescribing workflows, determines what each request needs, fills and submits forms, and tracks status.
For the medication side of nephrology — SGLT2 inhibitors, oral phosphate binders, anything moving through the pharmacy benefit — the reach is hard to match, and the integration is usually already sitting in your EHR.
Fits: practices whose authorization pain is concentrated in pharmacy-benefit medications, and who want something that works inside e-prescribing without a new implementation.
Honest weakness: it's built around medication prior authorization. The medical-benefit authorizations that drive nephrology's largest denials — dialysis, IV iron and ESAs administered in-office, imaging — are not its center of gravity. Most nephrology groups will need something else alongside it.
Availity
Availity is a health information network that consolidates payer connectivity, and it occupies a specific and useful position: much of what it offers providers costs nothing.
If your current process is staff logging into eight payer portals with eight sets of credentials, Availity collapses that into one place. It's the lowest-friction improvement available, and for smaller nephrology practices it may be enough.
Fits: practices early in their automation path, or any group that wants payer-portal consolidation without a procurement cycle.
Honest weakness: consolidation is not automation. Availity puts the portals in one window; a person still assembles the packet, attaches the labs, and submits. If your bottleneck is staff hours rather than credential sprawl, this doesn't solve it.
Silna Health
Silna Health is a newer provider-side AI platform aimed deliberately at the practices large revenue cycle suites underserve, with an emphasis on automating authorization and benefits verification end to end rather than assisting a human through the steps.
The pitch worth taking seriously is focus. A company doing one workflow for a defined customer segment tends to handle that segment's edge cases better than a suite doing forty workflows for everyone.
Fits: specialty practices and groups that want dedicated authorization automation without buying a full RCM platform.
Honest weakness: same caveat as any newer entrant — smaller installed base, and payer coverage that varies by market. Ask for their configured payer list against your top ten by volume before you get attached to the demo.
Cohere Health
Cohere Health is a matured startup working the authorization problem from the payer side, contracting with health plans to run utilization management and, in the process, making approvals faster and more predictable for the providers inside those plans.
It's on this list because the posture matters to your evaluation even though you probably won't buy it. If one of your major Medicare Advantage plans runs Cohere, your experience with that plan's authorizations is partly determined by a vendor you didn't select.
Fits: not a provider purchase in most cases — worth knowing about because it shapes the payer side of your workflow.
Honest weakness: the incentives sit with the plan, not with your practice. Cohere improving a payer's process is good for you, but it isn't a substitute for provider-side automation, and it won't track your dialysis authorization expirations.
How to run the evaluation in 30 days
Shortlists get stale fast in this market. A structured 30-day process beats six months of demos.
Week 1 — measure your own baseline. Count last month's authorizations split by type (recurring, lab-gated, step-therapy). Time twenty of them. Pull your last 100 denials and sort each by one question: would different documentation have changed the outcome? That administrative-versus-clinical split is your ceiling, and no vendor can tell you what it is.
Week 2 — send the same three questions to every vendor. Do they track authorization expiration and renew ahead of lapse? Can they read discrete lab values with draw dates? Can they show their configured rule set against your top ten payers by volume? Written answers, not demo answers.
Week 3 — demo against your own cases. Bring three real authorizations: a dialysis renewal, an ESA request, and an SGLT2 inhibitor under a CKD indication. Watch the platform handle them. Generic demos hide exactly the gaps that matter here.
Week 4 — check references in your specialty. Ask each vendor for a nephrology or dialysis-heavy reference. A vendor who can't produce one isn't disqualified, but you should know you'd be their first, and price accordingly.
For context on what you're comparing against, the 2025 CAQH Index found electronic adoption for medical prior authorization at 40%, up from 31% two years earlier — meaning a majority of medical PAs still move through manual or partly manual channels. And the 2025 AMA Prior Authorization Physician Survey found practices spend 13 hours a week on authorization work, with 40% employing staff who do nothing else. Whatever you buy, that's the baseline it has to beat.
One more thing worth knowing: CMS-0057-F began phasing in during January 2026, requiring impacted payers to return standard decisions within 7 calendar days, expedited within 72 hours, and to provide specific denial reasons through APIs. Ask each vendor how they're using those APIs. The ones with a concrete answer have been paying attention.
Frequently Asked Questions
What's the difference between medical and pharmacy prior authorization software?
Pharmacy PA runs through the drug benefit and e-prescribing rails; medical PA covers procedures, imaging, and drugs administered in your office. Nephrology needs both — SGLT2 inhibitors typically go through pharmacy, while dialysis, IV iron, and in-office ESAs go through medical. Platforms built for one often handle the other poorly.
Do any of these platforms specialize in nephrology?
None market themselves as nephrology-only, which is why the configuration questions matter more than the marketing. What you're testing is whether a platform handles recurring authorization renewal, lab-gated criteria, and indication-specific step therapy — the three places nephrology diverges from the general case.
How much does prior authorization automation cost?
Pricing is usually per-authorization or per-provider per-month, and almost never published. Ask for pricing at your actual volume, confirm whether payer rule maintenance is included or an add-on, and compare against your measured current cost rather than against zero.
Can we use more than one platform?
Many practices do, usually pairing a pharmacy-focused tool already embedded in their EHR with a medical-benefit platform. It works, but it splits reporting across two systems, so decide up front where you'll track first-pass approval rate and turnaround time.
How long does implementation take?
Most run 6 to 12 weeks, gated by EHR integration and payer configuration rather than by the software. Groups that start narrow — one payer, one drug class — get to a measurable result faster than groups attempting a full cutover.
Will any of these eliminate our prior authorization staff?
No, and treat that claim as a red flag. Peer-to-peer reviews, appeals requiring new clinical arguments, edge-case indications, and unconfigured payers all still need a person. What changes is the mix of work — less packet assembly and hold time, more exception handling and payer relationship management.
